Exact Sciences Corporation
EXAS
Κατάταξη σε μετοχές
#1156
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Τιμή μετοχής
$104.91
Τελευταίος συγχρονισμός: 2026-03-23
Κεφαλαιοποίηση
$20.03B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
67.24%
Χώρα
US
Εμπόριο Exact Sciences Corporation (EXAS)
Κατηγορία
Healthcare
Κέρδη για την Exact Sciences Corporation (EXAS)
Κέρδη τον Dec 2025 TTM: $-203.89M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Exact Sciences Corporation, τα τρέχοντα κέρδη της εταιρείας είναι $-203.89M. Το 2024, η εταιρεία παρουσίασε κέρδη $-1.04B, μείωση σε σύγκριση με των κερδών του 2023 που ήταν $-201.75M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Exact Sciences Corporation από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-203.89M | -3.83% |
| 2025 | $-212.01M | -79.54% |
| 2024 | $-1.04B | 413.60% |
| 2023 | $-201.75M | -68.11% |
| 2022 | $-632.57M | -24.92% |
| 2021 | $-842.51M | 1.62% |
| 2020 | $-829.06M | 103.98% |
| 2019 | $-406.44M | 132.18% |
| 2018 | $-175.06M | 52.78% |
| 2017 | $-114.58M | -31.47% |
| 2016 | $-167.21M | 5.96% |
| 2015 | $-157.80M | 57.73% |
| 2014 | $-100.05M | 115.09% |
| 2013 | $-46.51M | -11.27% |
| 2012 | $-52.42M | 82.81% |
| 2011 | $-28.68M | 148.14% |
| 2010 | $-11.56M | 26.60% |
| 2009 | $-9.13M | -6.29% |
| 2008 | $-9.74M | -18.55% |
| 2007 | $-11.96M | -7.40% |
| 2006 | $-12.92M | -11.05% |
| 2005 | $-14.52M | -21.61% |
| 2004 | $-18.52M | -34.64% |
| 2003 | $-28.34M | -5.16% |
| 2002 | $-29.88M | -99.87% |
| 2001 | $-23.49B | 176,087.09% |
| 2000 | $-13.33M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $7.61B | -3,831.95% |
US
|
|
| $4.76B | -2,435.60% |
US
|
|
| $-252.70M | 23.94% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -913.19% |
US
|
